
Luspatercept,
Form: Lyophilized powder for subcutaneous injection
Strength: 25 mg, 75 mg
Reference Brands: Reblozyl
Category: Anemia
Luspatercept is a groundbreaking erythroid maturation agent used to treat anemia in patients with beta thalassemia and myelodysplastic syndromes (MDS). Marketed under the brand name Reblozyl, it is approved by the FDA and EMA for reducing red blood cell transfusion dependence. Luspatercept is a recombinant fusion protein administered via subcutaneous injection and produced under strict GMP compliance. Ideal for pharmaceutical distributors, wholesalers, and B2B partners seeking high-demand biologics. We offer global bulk supply, regulatory support, and competitive pricing for Luspatercept. Partner with us for reliable sourcing and efficient delivery. Contact us now for Luspatercept export and distribution solutions.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Deferoxamine
Strength: 500 mg/vial, 2 g/vial
Form: Lyophilized powder for injection
Reference Brands: Desferal
View Details Get EnquiryDeferasirox
Strength: 125 mg, 250 mg, 500 mg
Form: Tablets for Oral Suspension
Reference Brands: Exjade, Jadenu (film-coated)
View Details Get EnquiryIron(III)-Isomaltoside Injection
Strength: 100mg/ml
Form: Injection
Reference Brands: Monofer,, Diafer, Monoferric
View Details Get EnquiryIron Dextran
Strength: 50 mg/mL
Form: injection
Reference Brands: Dexferrum,INFeD
View Details Get Enquiry